Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biomarkers Evaluated for Lung Disease Severity in Cystic Fibrosis

By LabMedica International staff writers
Posted on 22 Jun 2020
Cystic fibrosis (CF) is one of the most common life-shortening monogenic disorders amongst European-derived populations currently affecting more than 85,000 patients worldwide. More...
The diagnosis of CF is based on consensus clinical and laboratory criteria.

To confirm a diagnosis of CF, it is necessary to obtain evidence of CF transmembrane conductance regulator (CFTR) dysfunction through the identification of two CFTR gene mutations in trans previously assigned as CF disease causing, and to perform tests showing high chloride concentration in sweat, distinctive transepithelial nasal potential difference (NPD) measurements and/or assessment of CFTR (dys)function in native colonic epithelia ex vivo.

An international team of medical laboratory scientists led by the University of Debrecen (Debrecen, Hungary) have reviewed the methods used to diagnose CF. Monitoring of pulmonary inflammation via peripheral blood biomarkers is the most common strategy that could be analytically standardized and is generally reproducible. The team summarized the utility of thus far studied blood-, sputum- and bronchoalveolar lavage (BAL)-based biomarkers to evaluate inflammatory conditions in the lung and to follow treatment efficacy in CF.

Serum or plasma C-reactive protein (CRP) concentrations as indicators of systemic inflammation in CF have been analyzed and found to be increased in CF. Higher baseline plasma CRP levels (≥5.2 mg/L) were found in adult CF patients who had a more severe disease and were at higher risk for pulmonary exacerbation (PEx). Similarly, serum CRP was among those individual biomarkers, which could effectively differentiate CF children for lung disease severity.

Airway disease is characterized by chronic infection and recurrent inflammation with neutrophil dominance in association with increased production of a number of pro-inflammatory cytokines, such as IL-6, IL-8 and tumor necrosis factor-α (TNF-α). Serum IL-6 separated CF subjects from normal individuals and showed a significant reduction during antibiotic therapy. Similarly, plasma IL-8 monitored antibiotic efficacy by 21 days and indicated the onset of early re-exacerbation. Higher plasma IL-6 and IL-8 concentrations at the time of exacerbation were associated with an increased risk for being a non-responder to antibiotics.

Activated neutrophils produce several proteins under inflammatory conditions, such as NE, myeloperoxidase (MPO), calprotectin, YKL-40, etc., which circulate at a high quantity in CF blood specimens. NE is a ‘destructive’ serine protease impacting extracellular matrix proteins that forms complexes with anti-proteases leading to neutrophil elastase-antiprotease complex (NE-APC). Plasma NE-APC was elevated in persons with CF versus non-CF controls. The effect of repeated antibiotic therapy was significant on serum MPO levels and was thus utilized in assessing therapeutic efficacy in PEx. Recent discovery of new protein (e.g. human epididymis protein) and RNA-based biomarkers, such as microRNAs may offer a higher efficacy, which in aggregate may be valuable to evaluate disease prognosis and to substantiate CF drug efficacy.

The authors concluded that the field of biomarker development is rapidly evolving whereby it is expected that various omics technologies will be utilized together with advanced bioinformatics algorithms in order to grasp the multisystem complexity of CF disease in various stages of its development. The study was published online on May 16, 2020 in the journal Clinica Chimica Acta.

Related Links:
University of Debrecen


New
Gold Member
Hybrid Pipette
SWITCH
Collection and Transport System
PurSafe Plus®
Alcohol Testing Device
Dräger Alcotest 7000
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: The collaboration aims to improve access to Hb variant testing with the Gazelle POC diagnostic platform (Photo courtesy of Hemex Health)

Terumo BCT and Hemex Health Collaborate to Improve Access to Testing for Hemoglobin Disorders

Millions of people worldwide living with sickle cell disease and other hemoglobin disorders experience delayed diagnosis and limited access to effective care, particularly in regions where testing is scarce.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.